Jeff Kucharski

2.1k total citations · 1 hit paper
10 papers, 656 citations indexed

About

Jeff Kucharski is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jeff Kucharski has authored 10 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Cancer Research. Recurrent topics in Jeff Kucharski's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer, Lipids, and Metabolism (2 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). Jeff Kucharski is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer, Lipids, and Metabolism (2 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). Jeff Kucharski collaborates with scholars based in United States and South Korea. Jeff Kucharski's co-authors include Linda Kessler, Pingda Ren, Lian‐Sheng Li, Matthew R. Janes, Anjali Babbar, Tess Ely, Matthew P. Patricelli, Rasmus Hansen, Jeffrey H. Chen and Ulf Peters and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and European Journal of Cancer.

In The Last Decade

Jeff Kucharski

10 papers receiving 643 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

2016 530 citations Matthew P. Patricelli, Matthew R. Janes et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Jeff Kucharski

Since Specialization

Citations

This map shows the geographic impact of Jeff Kucharski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Kucharski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Kucharski more than expected).

Fields of papers citing papers by Jeff Kucharski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Kucharski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Kucharski. The network helps show where Jeff Kucharski may publish in the future.

Co-authorship network of co-authors of Jeff Kucharski

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Kucharski. A scholar is included among the top collaborators of Jeff Kucharski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Kucharski. Jeff Kucharski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State breakdown → 2016 ·Cancer Discovery ·Matthew P. Patricelli, Matthew R. Janes, Lian‐Sheng Li, Rasmus Hansen, Ulf Peters, Linda Kessler, Yuching Chen, Jeff Kucharski, Jun Feng, Tess Ely, Jeffrey H. Chen, Sarah J. Firdaus, Anjali Babbar, Pingda Ren, Yi Liu	530
2	Discovery of novel menin-MLL small molecule inhibitors that display high potency and selectivity in vitro and in vivo 2016 ·European Journal of Cancer ·Linda Kessler, (unknown), Jolanta Grembecka, Tomasz Cierpicki, Trupta Purohit, Hui Miao, Katarzyna Kempińska, Timothy D. Ely, (unknown), (unknown), (unknown), (unknown), Jeff Kucharski, (unknown), Yan Yao, Kai Yu, (unknown), (unknown), Pingda Ren, (unknown)	2
3	Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function* 2012 ·Journal of Biological Chemistry ·Lomon So, Sung Su Yea, Jean Oak, Mengrou Lu, (unknown), (unknown), Matthew R. Janes, Linda Kessler, Jeff Kucharski, Lian‐Sheng Li, Michael Martin, Pingda Ren, Katti Jessen, Yi Liu, Christian Rommel, (unknown)	59
4	Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer 2012 ·Cancer Research ·Shunyou Wang, (unknown), (unknown), Katti Jessen, Linda Kessler, Jeff Kucharski, Xin Guo, Jocelyn Staunton, (unknown), (unknown), (unknown), Levan Darjania, (unknown), Katrina Chan, (unknown), Pingda Ren, Christian Rommel, Yi Liu	4
5	Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. 2011 ·Molecular Cancer Therapeutics ·Katti Jessen, Linda Kessler, Jeff Kucharski, Xin Guo, Jocelyn Staunton, Matthew R. Janes, (unknown), (unknown), (unknown), Shunyou Wang, (unknown), (unknown), Levan Darjania, Lian‐Sheng Li, Katrina Chan, (unknown), Pingda Ren, Christian Rommel, Yi Liu	14
6	Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer 2011 ·Cancer Research ·Shunyou Wang, Katti Jessen, Linda Kessler, Jeff Kucharski, (unknown), Xin Guo, Jocelyn Staunton, (unknown), (unknown), Levan Darjania, Lian‐Sheng Li, Katrina Chan, (unknown), Pingda Ren, Christian Rommel, Yi Liu	1
7	Abstract 4501: INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer 2011 ·Cancer Research ·Katayoun A. Jessen, Linda Kessler, Jeff Kucharski, Xin Guo, Jocelyn Staunton, (unknown), Matthew R. Janes, (unknown), Shunyou Wang, (unknown), Levan Darjania, Lian‐Sheng Li, Katrina Chan, Michael Martin, Pingda Ren, (unknown), Christian Rommel, Yi Liu	5
8	Abstract 1668: Pharmacodynamic biomarker development for INK128, a potent and selective inhibitor of TORC1/2 for the treatment of cancer 2010 ·Cancer Research ·Katayoun A. Jessen, Shunyou Wang, Xin Guo, Linda Kessler, Jeff Kucharski, Jocelyn Staunton, (unknown), (unknown), (unknown), (unknown), Lian‐Sheng Li, Katrina Chan, Michael Martin, Pingda Ren, Christian Rommel, Yi Liu	1
9	Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity 2009 ·Molecular Cancer Therapeutics ·Katayoun A. Jessen, Shunyou Wang, Linda Kessler, Xin Guo, Jeff Kucharski, Jocelyn Staunton, (unknown), (unknown), (unknown), (unknown), Lian‐Sheng Li, Katrina Chan, Michael Martin, Pingda Ren, Christian Rommel, Yi Liu	20
10	2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3) 2008 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Linda Kessler, Jeff Kucharski, Jan O. Lundström, Stephen C. Miller, Hiroshi Nakanishi, Yazhong Pei, Kent E. Pryor, Edward Roberts, (unknown), (unknown), Ján Urban, Zhijun Wang	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact